CalciMedica, Inc.
CALCHealthcare|Biotechnology|US
$1.36
+0.06 (+4.62%)
DCF Value
$0.00
Tangible Book / Share
$1.61
Cash / Share
$5.44
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04195347 Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase | Acute Pancreatitis | P1P2 | Recruiting | 42 | Open-label | CM4620 |
| NCT04661540 A Study of Auxora in Patients With Critical COVID-19 Pneumonia | Pneumonia | P2 | Terminated | 10 | RCT, Single-blind | CM4620-IE (Injectable Emulsion), Placebo |
| NCT03709342 A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis | Acute Pancreatitis | P2 | Completed | 7 | Open-label | CM4620-IE |
| NCT03401190 CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS | Acute Pancreatitis, Systemic Inflammatory Response Syndrome | P2 | Completed | 21 | RCT, Open-label | CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose) |
| NCT04681066 A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS | Acute Pancreatitis, Systemic Inflammatory Response Syndrome | P2 | Completed | 216 | RCT, Double-blind | CM-4620 Injectable Emulsion or CM-4620-IE |
| NCT04345614 A Study of Auxora in Patients With Severe COVID-19 Pneumonia | Pneumonia | P2 | Completed | 314 | RCT, Double-blind | Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2), Placebo (Part 2) |
| NCT06374797 A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" | Acute Kidney Injury | P2 | Terminated | 122 | RCT, Double-blind | Auxora, Placebo |
| NCT05171920 A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia | Pneumonia | P2 | Withdrawn | — | RCT, Double-blind | Auxora, Placebo |